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Abstract 
The Reelin signaling protein and its downstream components have been associated with 
the etiopathogenesis of Alzheimer’s disease (AD). The Reelin signaling pathway begins 
with the binding of Reelin to the transmembrane lipoprotein-receptor, apolipoprotein E 
receptor 2 (ApoER2), which in turns induces the sequential cleavage of ApoER2 by the 
sequential action of α- and γ-secretases. Using conditional knockout mice of the catalytic 
component of the γ-secretase complex, presenilin 1 (PS1), we demonstrate increased brain 
ApoER2, and Reelin protein and transcript levels, with no changes in the number of 
Reelin-positive cells.  Using the human SH-SY5Y neuroblastoma cell line we demonstrate 
that ApoER2 processing occurs in the presence of PS1, resulting in an intracellular C-
terminal ApoER2 fragment. In addition, the pharmacological inhibition of γ-secretase in 
SH-SY5Y cells leads to increased Reelin levels. Over-expression of ApoER2 decreases 
Reelin mRNA levels in these cells. A luciferase reporter gene assay and nuclear 
fractionation confirm that increased amounts of intracellular fragment of ApoER2 suppress 
Reelin expression at a transcriptional level. Chromatin immunoprecipitation experiments 
corroborate that the intracellular fragment of ApoER2 binds to the RELN promoter region. 
Our studies suggest that PS1/γ-secretase-dependent processing of the Reelin receptor 
ApoER2 inhibits Reelin expression and may regulate Reelin signaling. 
 
Key words:  Alzheimer’s disease; Reelin; ApoER2; Presenilin-1; processing; 
transcription.  
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Introduction  
Alzheimer’s disease (AD), the most common cause of dementia among the elderly, is 
characterized by the presence in the brain of senile plaques and neurofibrillary tangles.  
The major component of the extracellular senile plaques is the β-amyloid protein (Aβ).  
This small polypeptide is generated by processing of the larger transmembrane β-amyloid 
precursor protein (APP; 1,2), by the successive action of proteolytic enzymes known as 
secretases (3). The intracellular neurofibrillary tangles are composed of paired helical 
filaments of the microtubule-associated protein tau, which is abnormally 
hyperphosphorylated (4).  
Reelin is a large signaling protein which plays an important role in the adult brain, 
influencing neurotransmission and synaptic plasticity. Normal Reelin levels are essential 
for some forms of long-term memory (5-7). Increasing evidence suggests that Reelin 
signaling is altered in the AD brain (8,9), but the pathophysiological significance and 
subsequent implications of these changes in the diseased brain remains unknown.  
The Reelin signaling pathway is initiated by binding of Reelin to transmembrane 
lipoprotein-receptors, the apolipoprotein E receptor 2 (ApoER2) and/or the very-low-
density liporeceptor (VLDLR) (10,11). Reelin receptors are also receptors for 
apolipoprotein E; which ApoE4 variant is the largest known genetic risk factor for late-
onset sporadic AD (12). Reelin binding induces the cleavage of Reelin receptors by the 
sequential processing of α- and γ-secretases which also process APP (13-15). Binding of 
Reelin to its receptor relays the signal into the cell via the adapter Dab1 (Disabled-1;16-
18).  Reelin-dependent induction of Dab1 tyrosine phosphorylation triggers an 
intracellular kinase cascade, which ultimately inhibits glycogen synthase kinase-3β 
(GSK-3β), preventing tau hyperphosphorylation (19). Reelin and Dab1 have both been 
shown to interact with APP (20-22) and influence its trafficking and processing (23-24). 
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We have also recently demonstrated that Aβ alters Reelin expression in the AD brain 
(8-9).  
In this study, we investigated if modulation of ApoER2, the major Reelin 
receptor in the brain, influences Reelin expression. We also studied the role of 
presenilin 1 (PS1), the active proteolytic component of the γ-secretase complex (25), in 
this modulation, as ApoER2 cleavage after its binding to Reelin is mediated by 
secretases. We used a PS1 conditional knockout mouse model (PS1 cKO; 26) to study 
the effect of PS1 on ApoER2, and on protein and mRNA levels of Reelin in vivo. Using 
SH-SY5Y cells over-expressing ApoER2, we establish that the C-terminal ApoER2 
fragment (CTF) is processed by γ-secretase, generating an intracellular domain 
fragment (ICD) that has transcriptional activity. 
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Methods 
PS1 conditional knockout mice 
Generation and characterization of PS1 cDKO mice have been previously described   
(26). PS1 cDKO mice lack expression of PS1 gene in glutamatergic neurons of the 
forebrain at postnatal stage starting around P18. PS1 cDKO mice (fPS1/fPS1;CaMKIIα-
Cre) were obtained by crossing floxed PS1 (fPS1/fPS1) males to PS1 cKO  females 
(fPS1/fPS1;CaMKIIα-Cre). Mice used in this study were age-matched littermate control 
(fPS1/fPS1) and PS1 cDKO (fPS1/fPS1; CaMKIIα-Cre) mice (background C57BL/6). 
Experimental procedures were conducted according to the Animal and Human Ethical 
Committee of the Universitat Autònoma de Barcelona (protocol CEEAH 475) following 
the European Union guidelines. 
Brain samples were collected from 3-4 month old PS1 cKO  (n=10) and age-
matched control littermates (n=10). No PS1 was detectable in the forebrain 
glutamatergic neurons of 2–3 month old mice, and no significant alterations in general 
behaviour, motor coordination, and exploratory anxiety were observed. Brain 
cytoarchitecture, neuronal numbers and morphology was also normal (26,27). 
 
Pharmacological treatment of SH-SY5Y neuroblastoma cells 
SH-SY5Y cells (220,000 cells/ well) were grown on 12 well-plates for 24 h in D-
MEM+GlutaMAX™ (Dulbecco’s Modified Eagle medium; Gibco®, life technologies 
Paisley, UK) supplemented with 10% fetal bovine serum (Gibco) and 100 µg/mL 
penicillin/streptomycin (Gibco). Cells were treated with 5 µM of γ-secretase inhibitor 
N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT; 
Calbiochem®, Merck KGaA, Darmstadt, Germany ) or vehicle Dimethyl Sulfoxide 
(DMSO). Following 22 h of treatment, the cells were washed twice with cold 
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Phosphate-saline buffer (PBS) and resuspended in 100 µL of ice-cold extraction buffer: 
50 mM Tris-HCl, pH 7.4 / 150 mM NaCl / 5 mM EDTA / 1% (w/v) Nonidet P-40 / 
0.5% (w/v) Triton X-100 supplemented with a cocktail of protease inhibitors. Cell 
lysates were sonicated and centrifuged at 20,000×g at 4ºC for 12 min, and extracts 
frozen at -80ºC for future analysis. 
Cell viability was measured using the tetrazolium assay (MTS; CellTiter 96® 
AQueous Assay, Promega, Southampton, UK) according to the manufacturer’s 
instructions. SH-SY5Y cells were cultured in 96-well plates (19,000 cells/well) and 
treated with DAPT as previously described. MTS was added after DAPT treatment and 
cells were incubated for 4 h, before viability was determined by measuring the 
absorbance at 490nm in a microplate reader (Infinite M200, Tecan; Männedorf, 
Switzerland).  
 
ApoER2 over-expression, RNA interference and luciferase reporter assay 
SH-SY5Y cells were transfected with a construct encoding full-length ApoER2 
(pEGFPN1-Mus musculus ApoER2). Alternative ApoER2 constructs were also used: 
ApoER2-myc expressing the transmembrane and cytoplasmic domains (amino acids 
825-963); and ApoER2-HA expressing only the cytoplasmic domain (amino acids 728-
842) (both generously provided by Dr W. Rebeck; see ref. 28, 29). Empty vectors 
(Promega) were used as control. Cells (650,000 cells/well) were grown in 6 well plates 
and transfected using Lipofectamine 2000 (Invitrogen™, life technologies Paisley, UK) 
according to the manufacturer´s instructions. After two days in culture, cells and culture 
supernatants were separately harvested. Cell culture supernatants were cleared by 
centrifugation for 10 min, 5000×g at 4ºC. Cells were extracted as previously described 
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and ApoER2 levels were assayed by Western blotting to determine transfection 
efficiency. 
For the luciferase reporter assay, cells were transfected with a pGL3 Basic 
Vector-RELN promoter (-2600 region which contains 2.6 kb of 5’ flanking sequence of 
human RELN promoter (a kind gift of Dr. D. Grayson; see ref. 30) in the presence of 
ApoER2-pEGFP or a pEGFP empty vector.  2-4 µg of each cDNA was co-transfected 
with 10-30 ng of the pRL-CMV vector (Renilla luciferase, Promega) in each well of a 
12-well plate (200,000 cells/well). Firefly and Renilla luciferase activities were 
measured using the Dual-Luciferase® Reporter Assay System (Promega). Cell lysates 
were prepared 36 h after transfection using Passive Lysis Buffer (Promega), and 
aliquots (~20 µl) were used for determination of luciferase activity in a SIRUS 
Luminometer V3.1 (Berthold Detection Systems GmbH, Germany). Firefly luciferase 
data were normalized to Renilla luciferase activity. 
 
Nuclear protein fractionation 
SH-SY5Y cells were cultured in 10 cm2 culture plates (4,000,000 cells/ plate). 36 h after 
transfection with ApoER2-pEGFP or the pEGFP empty vector, cells were washed twice 
with cold PBS, and gently scraped off the plates with 10 ml of cold PBS. Cell debris 
was discarded by centrifugation for 5 min at 500×g, 4ºC. Cell lysis and isolation of 
cellular nuclei were performed using the QProteome Nuclear Protein kit (Qiagen, 
Crawley, UK) according to the manufacturer's instructions. Cytosolic and nuclear 
protein fractions were assayed by Western Blotting. 
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Western blotting 
Reelin levels were determined as previously described (8). Brain extracts (30 μg), SH-
SY5Y cell extracts (30 μg) or cell culture media (~30 μl) were boiled for 3 min, then 
resolved on 6% polyacrylamide slab gels. Total protein concentration was determined 
by the bicinchoninic assay (Pierce, Thermo Scientific; IL USA). Electrophoresis was 
allowed to proceed at low voltage to minimize excessive heat generation (8,31). 
Proteins were blotted onto nitrocellulose membranes, blocked with 5% non-fat milk and 
incubated with monoclonal mouse anti-Reelin antibodies 142 (1:1000 dilution; 
Chemicon International,Merck KGaA, Darmstadt, Germany) for SH-SY5Y samples, 
and G10 (1:500 dilution; Chemicon) for mouse samples. These antibodies recognise 
epitopes located in the region of amino acids 164-189 (clone 142) and 164-496 (clone 
G10) (32).  
To detect ApoER2, brain and cell extracts were boiled for 7 min at 98ºC, and 
full length and C-terminal fragments of ApoER2 were resolved on 6% and 10% 
polyacrylamide gels respectively. A rabbit polyclonal antibody to ApoER2 (1:1000 
dilution; Abcam, Cambridge, UK), raised to a synthetic peptide corresponding to amino 
acids 928-945 located near the C-terminus of ApoER2, was used to detect ApoER2 and 
C-terminal fragments. APP-CTF was analyzed by 10% Tris-tricine SDS-PAGE and 
detected with a polyclonal rabbit anti C-terminal antibody (1:5000 dilution; Sigma- 
Aldrich). Rabbit polyclonal antibodies anti-HA (1:3000 dilution), anti-myc (1:3000 
dilution), (Sigma Aldrich), and mouse anti-GFP (1:3000 dilution; Abcam) were also 
used. Loading control was estimated using mouse α-tubulin (1:5000 dilution; Sigma-
Aldrich). A polyclonal antibody against acetylated histone H2B (AcH2B; 1:5000 
dilution) (generous gift of Dr. A. Barco) was used to characterize the nuclear fraction. 
Individual Western blots were used for each antibody to avoid stripping of immunoblots 
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and hence loss of signal. Immunoblots were developed with enhanced 
chemiluminescence (ECL) using SuperSignal (Pierce) in a Luminescent Image 
Analyzer LAS-1000 Plus (Fujifilm, Tokyo, Japan). The intensity of the Reelin bands 
was measured by densitometry using the Science Lab Image Gauge v 4.0 software 
provided by Fujifilm. 
 
Immunohistochemistry and immunocytochemistry 
Reelin levels were determined as previously described (8). Brain extracts (30 μg), SH-
SY5Y cell extracts (30 μg) or cell culture media (~30 μl) were boiled for 3 min, then 
resolved on 6% polyacrylamide slab gels. Total protein concentration was determined 
by the bicinchoninic assay (Pierce, Thermo Scientific; IL USA). Electrophoresis was 
allowed to proceed at low voltage to minimize excessive heat generation (8,31). 
Proteins were blotted onto nitrocellulose membranes, blocked with 5% non-fat milk and 
incubated with monoclonal mouse anti-Reelin antibodies 142 (1:1000 dilution; 
Chemicon International,Merck KGaA, Darmstadt, Germany) for SH-SY5Y samples, 
and G10 (1:500 dilution; Chemicon) for mouse samples. These antibodies recognise 
epitopes located in the region of amino acids 164-189 (clone 142) and 164-496 (clone 
G10) (32).  
To detect ApoER2, brain and cell extracts were boiled for 7 min at 98ºC, and 
full length and C-terminal fragments of ApoER2 were resolved on 6% and 10% 
polyacrylamide gels respectively. A rabbit polyclonal antibody to ApoER2 (1:1000 
dilution; Abcam, Cambridge, UK), raised to a synthetic peptide corresponding to amino 
acids 928-945 located near the C-terminus of ApoER2, was used to detect ApoER2 and 
C-terminal fragments. APP-CTF was analyzed by 10% Tris-tricine SDS-PAGE and 
detected with a polyclonal rabbit anti C-terminal antibody (1:5000 dilution; Sigma- 
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Aldrich). Rabbit polyclonal antibodies anti-HA (1:3000 dilution), anti-myc (1:3000 
dilution), (Sigma Aldrich), and mouse anti-GFP (1:3000 dilution; Abcam) were also 
used. Loading control was estimated using mouse α-tubulin (1:5000 dilution; Sigma-
Aldrich). A polyclonal antibody against acetylated histone H2B (AcH2B; 1:5000 
dilution) (generous gift of Dr. A. Barco) was used to characterize the nuclear fraction. 
Individual Western blots were used for each antibody to avoid stripping of immunoblots 
and hence loss of signal. Immunoblots were developed with enhanced 
chemiluminescence (ECL) using SuperSignal (Pierce) in a Luminescent Image 
Analyzer LAS-1000 Plus (Fujifilm, Tokyo, Japan). The intensity of the Reelin bands 
was measured by densitometry using the Science Lab Image Gauge v 4.0 software 
provided by Fujifilm. 
SH-SY5Y cells used for confocal microscopy were transfected with either 
ApoER2-pEGFP or a vector containing pEGFP alone using Lipofectamine 2000 
(Invitrogen) according to the manufacturers’s instructions. After 4 hours, media was 
replaced with fresh media containing 5 μM DAPT, or the equivalent volume of DMSO 
as control. After 24 hours, cells were washed with cold Hank´s buffered salt solution 
and fixed with methanol for 10 min at -20ºC. Non-specific sites were blocked with 2% 
(w/v) BSA and 40µg/ml digitonin in PBS for 30 min. Cells were then incubated with 
primary antibodies (rabbit anti-GFP 1:100 Invitrogen; mouse anti-Emerin 1:200 Santa 
Cruz Biotechnology , Santa Cruz, CA, USA; mouse anti-N Cadherin 1:200 ; BD 
Biosciences, Erembodegem, Belgium) for 1 hour followed by secondary antibodies 
(Alexa Fluor® 546 anti-mouse 1:200; Alexa Fluor® 488 anti-rabbit 1:200, Invitrogen) 
for 1 h. To study the location of ApoER2-EGFP in the vicinity of the inner nuclear 
membrane, cells were incubated with cycloheximide (50µM) (Sigma-Aldrich) for 2 
hours after transfection and before immunocytochemistry, to block synthesis of new 
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proteins. Pictures were acquired in a Leica upright TCL-SL confocal microscope (Leica 
Microsystems, Wetzlar, Germany) using an HCX Plan Apochromat 63×/1.32-0.6 NA 
oil objective (Leica). To measure the intensity of fluorescence of ApoER2-EGFP co-
localizing with emerin, a circle was hand drawn over the green fluorescence which 
overlaps the red fluorescent nuclear membrane in the merge channel, and fluorescence 
intensity analyzed by the LAS AF Lite software (Leica). 
 
RNA isolation and real-time RT-PCR analysis 
RNA was extracted from mouse brains and SH-SY5Y cells by TRIzol® Reagent in the 
PureLink™ Micro-to-Midi Total RNA Purification System (Invitrogen) following the 
manufacturer’s instructions. cDNAs were synthesized using SuperScript™ III Reverse 
Transcriptase(Invitrogen) according to the manufacturer’s instructions using 5 µg of 
total RNA and oligo (dT)12-18. Quantitative PCR amplification was performed using a 
StepOne™ Real-Time PCR System (Applied Biosystems; life technologies Paisley, 
UK) with TaqMan probes specific for mouse RELN (assay ID: Mm00465200_m1 
Applied Biosystems) and human RELN (assay ID: HS01022646_m1 Applied 
Biosystems), and mouse and human GAPDH as endogenous controls (Applied 
Biosystems). Reelin transcript levels were calculated using the relative standard curve 
method normalized to GAPDH. 
 
Chromatine Immunoprecipitation (ChIP) assay 
SH-SY5Y cells plated in 100-mm tissue culture dishes (4,300,000 cells/plate) were 
transfected with 20 μg of ApoER2-HA according protocol described above. After 36 h, 
cells were fixed in freshly prepared 1% paraformaldehyde for 10 min at room 
temperature. Cross-linking was halted by addition of 2.5 M glycine, 5 min. Cells were 
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washed twice with ice-cold PBS plus protease inhibitors. The chromatine was extracted 
using EZ Magna ChIP A/G (Millipore, Merck KGaA Darmstadt, Germany) according 
to manufacturer's protocol.  
Extracted chromatin was sheared to 100-500 bp using the BiorruptorTM 
(Diagenode Inc., USA), 30 s cycles for 10 min. After centrifugation at 10,000×g at 4°C 
for 10 min, the supernatant was collected. For immunoprecipitation, protein A/G 
magnetic beads (Millipore) were coupled to anti HA-antibody (Abcam) or to rabbit IgG 
antibody as a control (Millipore). Supernatants were incubated overnight with the beads. 
Immunoprecipitates were incubated with Proteinase K (Millipore) at 62ºC for 2 h 
(Thermomixer system; Eppendorf AG, Hamburg, Germany) to reverse the 
formaldehyde cross-linking, and purified DNA was analyzed by PCR, using primers for 
human GAPDH as control (Millipore). PCR amplification was performed using 30 ng 
of immunoprecipitated DNA in a 20 μl reaction volume containing 0,3 μM of sense and 
antisense primers, 10% v/v DMSO, and Kod Hot Start DNA Polymerase kit (Novagen, 
 Merck KGaA, Darmstadt)  (0.3 mM of each dNTP,  1X KOD Polymerase buffer, 1,5 
mM MgSO4 and 1 U of KOD Hot Start DNA Polymerase). Primers were designed to 
amplify 5´UTR human RELN at different positions of the promoter: [-515 to -395 bp] 
sense 5´- CTC GCT CAT TCA GTT TTG GAG-3´, antisense 5´- GGG GCT TTA AGA 
AGG TGT GG-3´; [-393 to -181 bp] sense:5´- CTC AGC GGT CCT CGA CAG-3´, 
antisense: 5´-CCG CTC CAC ACC TTC TTA AA-3; [-191 to +110 bp] sense 5´-CTC 
AGC GGT CCT CGA CAG-3´, antisense 5´- CCG CTC CAC ACC TTC TTA AA-3´. 
The assembly PCRs were carried out by an initial denaturation of DNA at 95°C for 5 
min. Cycling conditions were 32-35 cycles 30 s 94°C,  annealing at 61°C for 30s, 72°C 
for 30 s. A final extension period of 2 min at 72°C completed the thermocycling before 
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cooling. PCR products were analyzed by gel electrophoresis on a 2% Tris acetate-
EDTA (TAE) agarose gel.  
 
Statistical Analysis 
All data were analyzed by a Student’s t-test for single pair-wise comparisons using 
SigmaStat (Version 2.0; SPSS Inc.). Results are presented as means ±SEM. p values < 
0.05 were considered significant.  
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Results  
Reelin and ApoE receptor levels are altered in brains of PS1 cKO mice        
To determine if PS1 is involved in the control of Reelin receptor levels in vivo, brain 
homogenates from PS1 cKO mice (26) and littermate controls were first analyzed by 
SDS-PAGE followed by Western blotting. Immunoblotting for the main brain Reelin 
receptor, ApoER2, revealed a complex banding pattern probably reflecting the several 
ApoER2 isoforms (33), and mature and precursor forms (15,34). The levels of ApoER2 
appear to be significantly increased in cortical extracts from PS1 cKO mice (~80% 
increase) compared with controls (Fig. 1A). It is known that Reelin bound to ApoER2 
induces subsequent ApoER2 cleavage by the sequential action of α- and γ-secretases 
(13,15). α-Secretase cleaves the ApoER2 extracellular domain generating a membrane 
bound C-terminal fragment (CTF) which subsequently acts as a substrate for γ-
secretase.  Consistent with a role of PS1 in the proteolysis of ApoER2, we found a 
significant accumulation of ApoER2-CTF in cortical extracts from PS1 cKO mice 
(~300% increase) compared with controls littermate animals (Fig. 1A). Levels of 
ApoER2 in the cerebellum, a region in which PS1 is not silenced, did not differ between 
PS1 cKO mice and littermate controls (Fig. 1A).  
We next measured the levels of the ApoER2 ligand, Reelin, and found that full-
length Reelin (420 kDa) display a large increase in cortex of PS1 cKO mice (~200%), 
while N-terminal 310 kDa (~70%) and 180 kDa (~50%) Reelin fragments show 
moderate increase (Fig. 1B). Reelin levels in the cerebellum were similar in PS1 cKO 
mice and controls (Fig. 1B).   
To assess whether increased Reelin levels are due to a higher number of cells 
expressing Reelin in PS1 cKO mice, we labelled tissue sections with a specific antibody 
against Reelin and counted the number of stained cells (Fig. 2A). Density of Reelin-
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positive cells was similar in the cortex of control and PS1 cKO mice (Fig. 2B), 
indicating that differences in levels detected by Western blotting may be attributed to 
changes in the level of expression. A quantitative PCR assay was designed to determine 
whether changes in the Reelin protein corresponded to alterations in mRNA expression. 
Reelin mRNA levels were significantly increased (~20%) in the cortices from the PS1 
cKO mice compared to controls (p= 0.01; Fig. 2C). 
 
Inhibition of PS1/γ-secretase enhances Reelin levels in neuronal cells  
The SH-SY5Y neuroblastoma cell line was used to determine if altered ApoER2 
processing influences Reelin levels, and if this effect is mediated by γ-secretase. SH-
SY5Y cells express significant levels of Reelin and PS1 (9,35), and have been used as 
cellular models of ApoER2 over-expression (36). As previously mentioned, Reelin 
bound to ApoER2 induces subsequent ApoER2 cleavage by α- and γ-secretases. The 
CTF generates after α-secretase cleavage acts as a substrate for γ-secretase, which in 
turn yields an intracellular domain fragment (ICD) (for an illustrative scheme see Fig. 
3A). An ~25 kDa ApoER2-CTF fragment was observed in cell extracts from 
untransfected cells using a C-terminal ApoER2 antibody, in agreement with previous 
studies  (Fig 3B) (13,15,29). Endogenous ApoER2-ICD was not detected, probably due 
to its low levels and inherent instability (13). To further characterize the banding pattern 
for the ApoER2 CTF and the expected ICD fragment, a chimeric ApoER2 protein 
expressing the transmembrane and cytoplasmic domains tagged to myc (ApoER2 CTF-
myc) was over-expressed in SH-SY5Y cells.  Another chimeric ApoER2 protein 
containing only the cytoplasmic domain tagged to HA (ApoER2 ICD-HA) was also 
expressed (28,29). Cell extracts were then analyzed by Western blotting. An anti-myc 
antibody detected the ApoER2-CTF-myc at 25 kDa. A faint band of ~18 kDa was also 
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detected. This may correspond to an ICD-myc fragment resulting from processing of the 
longer ApoER2-CTF-myc. The specificity of the bands was confirmed by a C-terminal 
ApoER2 antibody (Fig. 3B). An 18 kDa band was also detected by the anti-HA 
antibody and the anti-C-terminal ApoER2 antibody in extracts of cells over-expressing 
ApoER2 ICD-HA, corresponding with the expected size of an ApoER2-ICD fragment 
(Fig. 3B).  
Previous studies show a similar processing mechanism for both APP and 
ApoER2 (37). The γ-secretase inhibitor DAPT has been demonstrated to reduce Aβ 
levels in vivo (38). The efficiency of DAPT to inhibit γ-secretase activity was monitored 
by measuring the accumulation of APP-CTF in SH-SY5Y cells (Fig. 4A). There was no 
cell death in cultures treated with 5 µM DAPT, as evaluated by the MTS assay (3 ±4% 
reduction, p= 0.7). Under identical conditions, treatment of the cells with DAPT 
inhibited γ-secretase-mediated processing of the ApoER2-CTF, resulting in increased 
levels of the endogenous 25 kDa ApoER2-CTF fragment (Fig. 4A). Interestingly, the γ-
secretase inhibitor induced an increase of cellular full-length Reelin levels (~40% 
increase, p= 0.003; Fig. 4B); by contrast, the 180 kDa Reelin fragment was not changed 
(~20% decrease; p= 0.3; Fig. 4B). Recent evidence indicates that this 180 kDa Reelin 
fragment is generated, at least in part, after interaction of full-length Reelin with 
ApoER2, initiating subsequent endocytosis and proteolysis (39). Our results suggest 
that Reelin processing may depend on ApoER2 binding. 
 
Modulation of ApoER2 expression in SH-SY5Y cells influences cellular Reelin 
expression 
To study the effect of ApoER2 over-expression on endogenous Reelin levels, SH-SY5Y 
cells were transfected for 48 hours with full-length ApoER2-EGFP. ApoER2-EGFP was 
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detected both intracellularly and at the plasma membrane (identified by staining with N-
Cadherin, a plasma membrane protein; Fig. 5A). Over-expression of ApoER2 leads to a 
significant decrease in secreted full-length Reelin measured in the culture medium (84 
±3%, decrease; Fig. 5B). The 180 kDa Reelin N-terminal fragment which is generated 
by extra and intracellular proteolysis (39-43) was not decreased (Fig. 5B), suggesting 
the increased levels of full-length Reelin is not dependent on the Reelin processing. 
Anyhow, the influence of ApoER2 in Reelin expression is difficult to address by 
measuring Reelin protein levels alone, since increases in the ApoER2 protein will also 
result in an increased binding to Reelin, and subsequent processing. 
We have shown that treatment of ApoER2 transfected SH-SY5Y cells with the 
γ-secretase inhibitor DAPT inhibits ApoER2-CTF processing (Fig. 4A). We then 
investigated the effect of γ-secretase inhibition in the production of ApoER2-ICD in 
SH-SY5Y cells over-expressing full-length ApoER2-EGFP. ApoER2-EGFP over-
expression resulted in immunoreactive bands with a shift in size due to the expected 
size of the EGFP tag (~25-30 kDa; Fig. 6A). Treatment of transfected cells with DAPT 
induced accumulation of CTF-EGFP (~50 kDa) and parallel decreased generation of the 
ICD-EGFP (~42 kDa band) (Fig. 6B). 
Immunofluorescence labelling of emerine, a protein associated to the 
intranuclear lamina and located at the inner nuclear membrane (44), allowed us to 
examin the presence of ApoER2-EGFP at the internal side of the nuclear membrane and 
in the nuclear lamina (Fig. 6C). Co-localization of ApoER2-EGFP and emerin is 
decreased in transfected cells treated with DAPT compared to controls (35 ±2% 
decrease, p= 0.01; Fig. 6C). Western blotting and staining of cellular nuclear extracts 
with anti-GFP and anti-ApoER2 C-terminal antibodies confirm the presence of an ICD-
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EGFP in this fraction (Fig. 6D). These results suggest that the ApoER2-ICD is 
translocated to the nucleus. 
Quantitative PCR was used to determine whether increased ApoER2 levels, 
including the ApoER2-ICD, influences Reelin mRNA expression. Levels of the Reelin 
transcripts were significantly decreased (12 ±3%, p= 0.02) in ApoER2-EGFP over-
expressing cells compared to controls (Fig. 7A). A luciferase reporter gene assay under 
the control of the RELN 5' upstream region (Reelin-luc) was designed to further confirm 
whether ApoER2 modulates Reelin expression at the transcriptional level. We observed 
that over-expression of ApoER2 alone greatly reduced expression of Reelin-luc in 
transfected cells (47 ±8% decrease in luciferase activity, p< 0.001; Fig. 6B). Similar 
results were obtained when an ICD-HA was over-expressed instead of the ApoER2 full-
length protein (37 ±5% decrease in luciferase activity, p< 0.001; Fig. 7B). 
To confirm that an ApoER2-ICD binds to the endogenous RELN promoter, ChIP 
assays were performed. Lysates of SH-SY5Y cells transfected with ApoER2-ICD were 
immunoprecipitated with an anti-HA antibody, and the DNA that bound to HA was 
amplified by PCR with different primers designed for distinct regions of the RELN 
promoter. As shown in Figure 7C, ApoER2-ICD binds the RELN promoter between the 
positions -191 to +110 bp with no binding elsewhere. 
Altogether, these results demonstrate that ApoER2 influences Reelin at the 
transcriptional level, and this process may be mediated by the processing and 
subsequent generation of an ICD.
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Discussion 
A growing number of studies now demonstrate the participation of Reelin and elements 
of its signaling pathway in the pathophysiology of AD. Therefore, there is increasing 
interest in the interaction of members of the Reelin cascade with pathways affected in 
AD. We have investigated the influence of PS1, a key protein involved in AD 
pathogenesis, in Reelin processing and expression. 
Reelin binds to ApoER2, a transmembrane protein which belongs to the LDL-
receptor family, and this induces its cleavage in a similar manner to APP by secretases. 
In this study, we first confirmed that the γ-secretase catalytic subunit, PS1, participates 
in ApoER2 cleavage. The total level of full-length ApoER2 is increased in PS1 cKO 
mice, suggesting a role for PS1 in affecting expression or processing of ApoER2. The 
ApoER2-CTF accumulates in PS1 cKO mice and in cultured SH-SY5Y cells 
(untransfected or transfected with full-length ApoER2) treated with the γ-secretase 
inhibitor DAPT.  This CTF is likely to represent the penultimate proteolytic fragment 
before the final cleavage by γ-secretase, releasing the soluble intracellular ICD (13). 
Our data also indicate that the modulation of γ-secretase activity not only affects PS1-
processing of ApoER2, but also Reelin levels. We also demonstrate an effect on Reelin 
transcription. 
In PS1 cKO mice with decreased γ-secretase activity, levels of full-length Reelin are 
increased. Furthermore, inhibition of γ-secretase with DAPT increases the levels of full-
length Reelin in cell extracts; although the amounts of the 180 kDa N-terminal fragment 
of Reelin do not appear to be affected. In the PS1 cKO mouse brain, twice the amount 
of full-length Reelin is present compared to its N-terminal fragments. Any change in the 
level of full-length Reelin or its N-terminal fragments will reflect on Reelin processing 
which occurs in parallel with ApoER2 processing. Discrepancies between in vivo and in 
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vitro findings may also be related to the complex regulation of Reelin expression and 
signaling, as the capacity of the functional full-length Reelin to bind to its receptors is 
regulated by competition with the truncated Reelin fragments (45). Therefore, the in 
vivo control of Reelin expression and signaling might be intricate. 
Interestingly, the deficiency of γ-secretase in PS1 cKO mice also leads to an 
increase in Reelin mRNA. These results suggest that ApoER2 processing, mediated by 
Reelin binding and catalysed by PS1/γ-secretase, can in turn influence Reelin 
expression at the transcriptional level. Transmembrane proteins undergo γ-secretase 
cleavage culminating in the release of their ICDs, which translocate to the nucleus and 
acts as a transcriptional regulator (46). In contrast, the cleavage of other substrates 
seems to merely be a degradative function (for a review see 47). The Notch ICD 
represents the best γ-secretase substrate studied to date (48), and an ICD transcriptional 
activity has been also associated with APP (49). The generation of ICD fragments has 
been shown for other LRP family members (50-52), and its nuclear translocation 
inferred. Whether the ICD generated from ApoER2 processing has a transcriptional 
activity has been unknown, to date.  
Our current studies demonstrate that the inhibition of PS1-mediated ApoER2 
processing, and hence, the increase of CTF levels, also results in an increase in Reelin 
levels. Furthermore, when cells overexpress full length ApoER2, ApoER2-CTF levels 
are increased in comparison with untransfected cells, with a parallel rise in the ApoER2 
ICD to detectable levels in the cell extract. We observe a parallel reduction in levels of 
the extracellular Reelin protein, indicating that over-expression of full-length ApoER2 
promotes an increase in Reelin processing. Both, over-expression of full-length 
ApoER2 (and the subsequent increase in the ApoER2-ICD), or over-expression of the 
ApoER2-ICD, down-regulate RELN promoter activity through binding in the RELN 
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promoter region. Accordingly, an ApoER2-ICD is found in the soluble nuclear fraction 
after transfection of SH-SY5Y cells with full length-ApoER2. Interestingly, when cells 
overexpressing full length-ApoER2 are incubated with DAPT, the amount of ApoER2-
ICD is decreased, and is accompanied by a decrease in ApoER2-GFP fluorescence at 
the nucleus. These results suggest that the ApoER2-ICD can act as an inhibitor of 
Reelin synthesis.  
The potential modulation of the Reelin signaling pathway by γ-secretase has 
been previously explored in conventional PS1 KO mice (53). In this work, no difference 
in Reelin levels was observed between embryonic PS1 null mutant and wild type mice.  
The cellular pattern of Reelin expression has been demonstrated to differ between 
embryonic and adult brain. At the end of the neuronal migration period in embryos, 
Reelin is predominantly expressed by Cajal-Retzius neurons. These cells become 
eventually replaced principally by a subset of GABAergic interneurons in the adult 
brain (54). Indeed, it is thought that Reelin has distinct functions in the developing and 
in the adult brain (5). Changes in embryonic and adult expression pattern for the Reelin 
receptor ApoER2 are also expected. Therefore, differences between embryonic and 
adult brain in the cellular pattern of expression and in the regulation of Reelin and its 
receptors, may contribute to the divergent results observed in our studies. 
To our knowledge, this study is the first report demonstrating an autocrine loop 
modulating Reelin levels where Reelin binding activates the processing of its receptor, 
which in turns, regulates the levels of Reelin. Previous studies have shown that binding 
of Reelin to its receptors results in processing of the complex, releasing a secreted 
soluble ApoER2 fragment containing the entire ligand-binding domain. This domain 
acts in a dominant-negative fashion in the regulation of Reelin signaling (55). Our 
studies also demonstrate that ApoER2 modulation of Reelin levels could occur within 
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the cells themselves. The secretory nature of Reelin and the evidence of a “paracrine” 
biological activity in distal cells expressing ApoE receptors (56), has attracted much 
attention in neuropathology. Similar ligands for lipoprotein receptors such as ApoE 
have also been shown to act as an autocrine/paracrine factor (57). Evidence also 
suggests a role for Reelin in autocrine signaling. A dual role for Reelin in both autocrine 
and paracrine signaling has been recently suggested in neuroblastomas (58). 
Glutamatergic cerebellar granule neurons which synthesize Reelin, have been shown 
also to co-express ApoER2 (59). In addition, Reelin and Dab1, the intracellular 
component of the Reelin signaling cascade, are co-expressed in Cajal-Retzius neurons 
during cortical development and in cortical pyramidal neurons after neuronal migration 
is complete (60). Reelin and ApoER2 also co-localize in some cells in the adult mouse 
brain (not shown), and in ApoER2 enriched areas of the retina (33).  In situ 
hybridization studies demonstrate as well co-expression of Reelin and ApoER2 which 
are expressed in the same brain areas in the adult canary brain (61). These data support 
the idea that in the adult brain, the action of Reelin may take place within close vicinity 
of its synthesis. 
Interestingly, the processing of ApoER2 by γ-secretase is regulated by the 
glycosylation state of the receptor, which in turn is dependent on tissue-specific 
alternative splicing (13). Modulation of synaptic plasticity and memory by Reelin 
involves the differential splicing of ApoER2 (5).  Although the association of ApoER2 
polymorphisms with AD is not clear (62,63), altered glycosylation of Reelin in the 
Alzheimer’s brain may influence Reelin signaling and appears to be associated with 
progression of the disease (8,9). Binding affinities of Reelin for its receptors can also be 
modulated by competition with other ligands. The ApoE4 variant, the major known 
genetic risk factor for AD, is one of its strongest competitors (10). It has been recently 
24 
 
demonstrated that ApoE4 selectively impairs synaptic plasticity and NMDA receptor 
phosphorylation by Reelin (64). The isoform-specific role of ApoE in the localization 
and intracellular trafficking of ApoER2 and glutamate receptors reveals an alternative 
mechanism by which ApoE4 may accelerate onset of dementia and neuronal 
degeneration by differentially impairing the Reelin-dependent maintenance of synaptic 
stability (64). 
In conclusion, our studies suggest that PS1, a key enzyme in AD 
pathophysiology, influences Reelin expression. This is mediated by γ-secretase 
processing of the Reelin receptor ApoER2.  Our data and other recent findings suggest a 
scenario where Reelin signaling, in conjunction with APP trafficking and PS1 
processing of ApoER2, are cornerstones of an integrated signaling network that may be 
disrupted in the AD brain, compromising synaptic responsiveness, plasticity and 
survival.
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Figure Legends 
Figure 1.  Increased levels of ApoER2 and Reelin in the cortex of PS1 cKO mice. 
(A) Representative blot for immunodetection of ApoER2 full-length isoforms and CTF 
in the cortex (left panel) and the cerebellum (right panel) of control wild-type (WT; n= 
6) and PS1 cKO mice (n= 6). The densitometric quantification from the sum of all the 
bands close to 160 and 140 kD, and of the 25-kDa CTF band are shown.  (B) Western 
blots and densitometric quantification of Reelin fragments from the same WT and PS1 
cKO samples presented in (A). The N-terminal Reelin antibody G10 detects full-length 
420 kDa Reelin and the N-terminal 310 and 180-kDa fragments. Reelin 
immunoreactivity from each fragment is shown, and expressed as a percentage relative 
to immunoreactivity of the 420-kDa band from WT mice. Experiments were performed 
in triplicate, and α-tubulin was used as a loading control. The data represent the means ± 
SEM. *Significantly different (p < 0.01) from the WT group.  
 
Figure 2.  Unaltered number of cells expressing-Reelin in PS1 cKO mice and 
increased levels of Reelin mRNA. (A) Immunostaining of cortical tissue sections from 
control wild-type (WT) and PS1 cKO mice with the Reelin specific antibody G10. Scale 
bar: 100µm. (B) Scatter plots representing the number of Reelin-positive cells 
quantified by counting the number of stained cells in each section (n=36-40 sections, 4 
animals per group), including mean ±SEM. (C) Relative mRNA levels were analyzed 
by QRT-PCR in brain cortex from WT and PS1 cKO  mice (n= 8 each). Values were 
calculated using relative standard curves and normalized to GAPDH from the same 
cDNA preparations. Specifity of the PCR products was confirmed by dissociation curve 
analysis.  The results were confirmed in two independent determinations. The data 
represent the means ± SEM. *Significantly different (p < 0.05) from the WT group. 
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Figure 3. Diagram of ApoER2 and identification of intracellular fragments. (A) 
Diagram of the wild-type ApoER2 and chimeric proteins containing the ligand-binding 
domain (LBD), transmembrane domain (TMD) and cytoplasmic domain (CD). The two 
main processing sites by α- and γ-secretase are indicated, sequential secretase cleavage 
generates a membrane bound C-terminal fragment (CTF) and an intracellular domain 
fragment (ICD). (*)The epitope for the C-terminal antibody is approximately located as 
indicated. C-terminal tags for ApoER2 constructs are myc, HA and EGFP. (B) The 
endogenous ApoER2 fragments from untransfected SH-SY5Y cells (-) were identified 
by blotting with a C-terminal ApoER2 antibody; while chimeric proteins expressed in 
transfected cells (+) were identified by blotting with the anti C-terminal ApoER2 
antibody and with antibodies against the specific tag, as indicated. 
 
Figure 4. Inhibition of γ-secretase enhances Reelin levels. SH-SY5Y cells were 
treated for 24 hours in the presence of 5 μM of DAPT (+) or the vehicle (control; -), and 
ApoER2 and Reelin were assayed by Western blotting of cell extracts (equivalent 
amounts of protein were loaded in each lane). (A) Assessment of APP CTF levels 
serves as a control of the efficiency of DAPT to inhibit γ-secretase activity. The 
accumulation of ApoER2 CTF was monitored with a C-terminal anti-ApoER2 antibody. 
Data represent percentage relative to control cells. (B) Reelin from cell extracts was 
detected with an N-terminal antibody. Immunoreactivity of full-length Reelin at 420 
kDa and the predominant 180 kDa N-terminal fragment is shown, and expressed as a 
percentage relative to immunoreactivity of the 420-kDa band from control cells. The 
data represent the means ± SEM (determinations by duplicate). *Significantly different 
(p < 0.005) from the control group. 
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Figure 5. ApoER2 over-expression decreases full-length Reelin levels. (A) Confocal 
images of a SH-SY5Y cells transfected with full-length ApoER2-EGFP. Cells were 
incubated with an antibody against GFP to label ApoER2-EGFP and with an antibody 
against N-Cadherin to stain the plasma membrane. The merged image shows ApoER2 
localized in the plasma membrane (yellow) as well as intracellularly. The insets show 
magnification of the selected area. (B) ApoER2 over-expression influences Reelin 
secretion, assessed by an antibody against the N-terminal. Immunoreactivity of full-
length Reelin at 420 kDa and the predominant 180 kDa N-terminal fragment is shown, 
and expressed as percentage relative to immunoreactivity of the 420-kDa band from 
control cells. The data represent the means ± SEM (determinations by duplicate). 
*Significantly different (p < 0.001) from the control group transfected with an empty 
vector (-). 
 
Figure 6. An ApoER2-ICD is identified in the nucleus of full-length ApoER2-
EGFP over-expressing cells. (A) SH-SY5Y cells were transfected with ApoER2-
EGFP Endogenous and exogenous proteins were identified by blotting with anti C-
terminal ApoER2 and anti GFP antibodies (note the shift due to the EGFP tag). (B) The 
generation of CTF-EGFP and ICD-EGFP fragments was monitored in transfected cells 
treated with the γ-secretase inhibitor DAPT. ApoER2 fragments were detected with an 
anti-ApoER2 C-terminal antibody. Treatment with DAPT results in an increase of 
ApoER2-CTF (closes arrow-head) in cell extracts, whereas the ApoER2-ICD band 
(open arrow-head) is more abundant when γ-secretase activity is not inhibited. (C) 
Confocal images of SH-SY5Y cells transfected with full-length ApoER2-EGFP in the 
presence of DAPT. Cells were incubated for 1 hour with or without DAPT (control) 
before fixation with methanol followed by incubation with an antibody against GFP to 
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label ApoER2-EGFP fragments, and with an antibody against emerin, a nuclear protein 
associated to lamina. The insets show magnification of the selected area. Quantification 
of the ApoER2-EGFP fluorescence that co-localizes with Emerin is shown (for control 
n=166 cells, 2 independent experiments; for DAPT, n=131 cells, 2 independent 
experiments). *p< 0.001. (D) Nuclear fractions from SH-SY5Y cells transfected with 
full-length ApoER2-pEGFP or a pEGFP vector were analyzed by Western blotting with 
an anti-ApoER2 C-terminal antibody or anti-GFP. ApoER2-ICD was detected in the 
nuclear fraction of over-expressing cells. Acetylated histone H2B (AcH2B) and tubulin 
were used as markers for nuclear and cytoplasmic fractions respectively.  
 
Figure 7. ApoER2 over-expression down-regulates Reelin expression. (A) Reelin 
transcript levels were analyzed by qRT-PCR in SH-SY5Y cells transfected with full-
length ApoER2-pEGFP or a pEGFP vector (n= 10 each). Values were calculated using 
relative standard curves and normalized to GAPDH from the same cDNA preparations. 
Specifity of the PCR products was confirmed by dissociation curve analysis.  The 
results were confirmed in two independent determinations. *p< 0.01. (B) SH-SY5Y 
cells were co-transfected with RELN reporter plasmid and either full-length ApoER2-
EGFP (n= 12, 3 independent experiments) or ICD-HA (n= 8, 2 independent 
experiments). Empty vectors for each ApoER2 plasmid were used as controls. The 
activity was related to Renilla luciferase reporter. Over-expression of full-length 
ApoER2 and ApoER2-ICD diminishes the activity of the RELN promoter. **p< 0.001. 
(C) Scheme of the proximal region of the RELN promoter. The approximate positions 
of the known transcription factor binding sites are also indicated (CREB:▲; SP1: Δ; N-
Myc: ↑; Mzf1: ▲; Tbr1: ^), together with the position of the primers used for the ChIP 
analysis (horizontal arrows). SH-SY5Y cells transfected with ApoER2 ICD-HA were 
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also processed for ChIP with an antibody specific for HA or an unrelated rabbit IgG 
antibody as control, followed by PCR amplification of various regions of the RELN 
promoter indicated in the schematic above. Unprecipitated chromatin preparations were 
similarly analyzed and used as “input” control.  







